ProKidney Corp. Prepares for Major Healthcare Conferences

ProKidney Set for Upcoming Healthcare Conferences

WINSTON-SALEM, N.C. — ProKidney Corp. (Nasdaq: PROK), a leader in the clinical-stage cellular therapeutics field, is excited to announce that its senior management will be participating in two significant healthcare conferences this September. These conferences are an excellent opportunity for ProKidney to showcase its advancements and innovations in treating chronic kidney disease (CKD).

Citi Biopharma Back to School Conference

One of the first events on the agenda is the Citi Biopharma Back to School Conference. This event is scheduled for September 3 and will be hosted in Boston. The format will be a fireside chat, offering an intimate setting where discussions can easily flow. ProKidney’s engagement in this conference demonstrates its commitment to sharing insights and developments with key stakeholders in the healthcare community.

Event Details

The Citi Biopharma Conference will begin at 10:30 AM ET. Attendees can follow the discussion and gain valuable insights into the company's research and future plans. The session can be accessed through the Investor Relations section of ProKidney's website.

Morgan Stanley Global Healthcare Conference

Following the Citi event, ProKidney will participate in the Morgan Stanley Global Healthcare Conference, happening on September 8 in New York. This major conference is known for gathering prominent healthcare voices, and ProKidney is honored to be part of it.

What to Expect

Another fireside chat format will facilitate open discussions at 7:00 AM ET. ProKidney's executives will share key updates about the company's ongoing Phase 3 REGEN-006 study, highlighting the potential benefits of their leading product candidate, rilparencel. Attendees can expect in-depth conversation about ProKidney's innovations and how they aim to significantly improve the treatment landscape for CKD patients.

Access to Live Webcasts

For those interested in following the live coverage, both sessions will be available via webcast on ProKidney's website. This provides a perfect avenue for investors and interested parties to stay informed about the latest developments in the field of chronic kidney disease.

About ProKidney Corp.

ProKidney has positioned itself as a pioneer in treating chronic kidney disease through advanced cellular therapy innovations. Established in 2015, ProKidney's dedication stems from over a decade of extensive research. Its primary product, rilparencel, is celebrated for being the first of its kind and comes with proprietary and patented technology. This cellular therapy is currently undergoing evaluation in the ongoing Phase 3 trial, showing promise in preserving kidney function for advanced CKD patients, especially those alongside type 2 diabetes.

Further Information

Investors or professionals looking for more details about ProKidney executive insights or potential collaborations are encouraged to reach out through the official channels provided on the website.

Frequently Asked Questions

What is ProKidney Corp. known for?

ProKidney Corp. focuses on developing innovative therapies for chronic kidney disease, particularly through cellular therapeutic advancements.

When will ProKidney participate in the upcoming conferences?

ProKidney will participate in the Citi Biopharma Back to School Conference on September 3 and the Morgan Stanley Global Healthcare Conference on September 8.

What is rilparencel?

Rilparencel is ProKidney’s leading product candidate, recognized as a first-in-class cellular therapy aimed at preserving kidney function in patients with advanced CKD.

How can investors learn more about ProKidney?

Investors can visit ProKidney's website, specifically the Investor Relations section, for updates and access to webcasts of upcoming conference sessions.

Who can be contacted for investor relations?

For investor inquiries, Ethan Holdaway from ProKidney and Daniel Ferry from LifeSci Advisors are available for contact through their respective emails provided in the announcements.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.